NCT05196334

Pharmacotyping of Pancreatic Patient-derived Organoids

Recruiting now Last updated 3 October 2024

What this trial tests

trial testing No intervention in Pancreatic Cancer in 88 participants. Currently enrolling.

Timeline

1 July 2021

Primary endpoint
30 August 2025

31 August 2025

Quick facts

Lead sponsor	Herlev Hospital
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	88
Start date	1 July 2021
Primary completion	30 August 2025
Estimated completion	31 August 2025
Sites	1 location across Denmark

Drugs / interventions tested

• No intervention

Conditions studied

• Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Herlev Hospital

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EUS-FNB samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. The organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers.
   Pei L, Liu Y, Liu L, Gao S, et al · · 2023 · cited 170× · PMID 36759842 · DOI 10.1186/s12943-023-01731-z
2. Organoids: The current status and biomedical applications.
   Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
3. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
   Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
4. Applications of human organoids in the personalized treatment for digestive diseases.
   Wang Q, Guo F, Jin Y, Ma Y. · · 2022 · cited 43× · PMID 36167824 · DOI 10.1038/s41392-022-01194-6
5. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
6. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
   Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
7. Tumor-derived systems as novel biomedical tools-turning the enemy into an ally.
   Desai N, Katare P, Makwana V, Salave S, et al · · 2023 · cited 20× · PMID 37946275 · DOI 10.1186/s40824-023-00445-z
8. Functional Drug Screening in the Era of Precision Medicine.
   Napoli GC, Figg WD, Chau CH. · · 2022 · cited 16× · PMID 35879922 · DOI 10.3389/fmed.2022.912641